Publications by authors named "Krista Lanctot"

Objectives: Mentorship supports faculty to succeed in their careers with confidence, resilience, and satisfaction. To address inequities evident with an informal approach, a formal mentorship program was designed and implemented.

Methods: The Quality Implementation Framework (QIF) was applied.

View Article and Find Full Text PDF

Background: Study aims were to assess the current state and needs of faculty to inform the design of a formal mentorship program in a large academic Department of Psychiatry.

Methods: A 57- item self-administered online survey questionnaire was distributed to all faculty members.

Results: 225 faculty members completed the survey (24%).

View Article and Find Full Text PDF

Introduction: Post-traumatic stress disorder (PTSD) can have debilitating effects on quality of life, and conventional treatments show mixed results. Neuromodulation is emerging as a promising approach for treating PTSD. This review examines current neuromodulatory treatments for PTSD, and highlights methodologies, clinical outcomes, and gaps in the literature to help guide future research.

View Article and Find Full Text PDF

The Canadian Consortium on Neurodegeneration in Aging (CCNA) was created by the Canadian federal government through its health research funding agency, the Canadian Institutes for Health Research (CIHR), in 2014, as a response to the G7 initiative to fight dementia. Two five-year funding cycles (2014-2019; 2019-2024) have occurred following peer review, and a third cycle (Phase 3) has just begun. A unique construct was mandated, consisting of 20 national teams in Phase I and 19 teams in Phase II (with research topics spanning from basic to clinical science to health resource systems) along with cross-cutting programs to support them.

View Article and Find Full Text PDF

Introduction: Elevated plasma homocysteine (Hcy) is associated with an increased risk of developing neurodegenerative diseases; however, its relationship with the apolipoprotein E (APOE) ε4 allele has not been well characterized.

Methods: Participants clinically diagnosed with Alzheimer's disease or mild cognitive impairment (AD/MCI), frontotemporal dementia, Parkinson's disease, or cerebrovascular disease were stratified by the presence of the APOE ε4 allele. Volumetric magnetic resonance imaging, plasma amyloid/tau/neurodegeneration biomarkers, and cognitive performance were quantified.

View Article and Find Full Text PDF
Article Synopsis
  • Older adults with major depressive disorder (MDD) or mild cognitive impairment (MCI) are at increased risk for cognitive decline, making effective interventions crucial.
  • This study aimed to evaluate the effectiveness of combining cognitive remediation (CR) and transcranial direct current stimulation (tDCS) on cognitive decline in older adults with remitted MDD (rMDD) and/or MCI.
  • Results indicated that this intervention slowed cognitive decline over time but did not lead to immediate improvements in cognition after 2 months.
View Article and Find Full Text PDF

Mild cognitive impairment (MCI) is a prodromal stage in aging to possible progression to Alzheimer's disease and related dementia (ADRD), where co-occurrence of major depressive disorder (MDD) accelerates the progression. Metabolic and mitochondrial abnormalities in ADRD and other neurodegenerative disorders have been widely suggested, while possible mitochondrial dysfunction has been associated with etiopathology of both MCI and MDD. Hence, investigation of mitochondrial markers in MCI, MDD, and presence of both conditions is warranted.

View Article and Find Full Text PDF

Objectives: Among participants with Alzheimer's disease (AD) we estimated the minimal clinically important difference (MCID) in apathy symptom severity on three scales.

Design: Retrospective anchor- and distribution-based analyses of change in apathy symptom scores.

Setting: Apathy in Dementia Methylphenidate Trial (ADMET) and ADMET 2 randomized controlled trials conducted at three and ten clinics specialized in dementia care in United States and Canada, respectively.

View Article and Find Full Text PDF
Article Synopsis
  • In 2020, the Lancet Commission identified 12 factors that can be modified to reduce the risk of dementia, but how these factors relate to each other in individuals is not well understood.
  • Researchers analyzed data from over 118,000 dementia-free adults aged 60-64 from the UK Biobank, identifying three distinct profiles of dementia risk based on sex: cardiometabolic risk, substance use risk, and low risk.
  • The cardiometabolic risk profile was linked to significantly higher rates of dementia, worse cognitive performance, and more brain changes, while substance use had mixed effects depending on sex, and the impact of genetic risk factors varied across the profiles.
View Article and Find Full Text PDF

Aims: This study examined serum cytochrome P450-soluble epoxide hydrolase (CYP450-sEH) oxylipins and depressive symptoms together in relation to cognitive performance in individuals with type 2 diabetes mellitus (T2DM).

Methods: Clinically cognitively normal T2DM individuals were recruited (NCT04455867). Depressive symptom severity was assessed using the Beck Depression Inventory-II (BDI-II; total scores ≤13 indicated minimal depressive symptoms and ≥ 14 indicated significant depressive symptoms).

View Article and Find Full Text PDF

The purpose of this study was to investigate relationships between depressive symptoms, functional disability, and physical activity over time in community-dwelling older adults. The Religious Order Study and Rush Memory and Aging Project are longitudinal cohort studies based in the United States which began recruitment in 1994 and 1997, respectively. This analysis included 1611 participants (27.

View Article and Find Full Text PDF
Article Synopsis
  • Major depressive disorder (MDD) is a serious illness that affects many people and can make life really tough, and some people don't feel better with regular treatments.
  • A new study is testing a substance called psilocybin, which has shown promise in helping some people with depression quickly.
  • The research will look at how psilocybin affects the brain and mood over time compared to a placebo (fake treatment) in 50 participants suffering from MDD.
View Article and Find Full Text PDF

Objectives: To examine clinically important adverse events (AEs) associated with methylphenidate (MPH) treatment of apathy in Alzheimer's Disease (AD) versus placebo, including weight loss, vital signs, falls, and insomnia.

Methods: The Apathy in Dementia Methylphenidate Trial 2 (ADMET2) trial was a multicenter randomized, placebo-controlled trial of MPH to treat apathy in individuals with apathy and AD. Participants in ADMET2 had vital signs and weight measured at monthly visits through 6 months.

View Article and Find Full Text PDF

Unlabelled: Theta-gamma coupling (TGC) is a neurophysiological process that supports working memory. Working memory is associated with other clinical and biological features. The extent to which TGC is associated with these other features and whether it contributes to working memory beyond these features is unknown.

View Article and Find Full Text PDF
Article Synopsis
  • Agitation, psychosis, and apathy are common neuropsychiatric symptoms in Alzheimer's disease that lead to serious issues like increased mortality and caregiver burden, and current treatments may have serious side effects.
  • This review focuses on new and repurposed drugs, including atypical antipsychotics and other medications, that have been tested in clinical trials for effectively managing these symptoms.
  • Promising treatments include novel atypical antipsychotics and antidepressants for agitation, Pimavanserin for psychosis, and methylphenidate for apathy, although more research is needed to improve understanding and treatment outcomes.
View Article and Find Full Text PDF

Background: Neurofilament Light Chain (NfL) is a biomarker of axonal injury elevated in mild cognitive impairment (MCI) and Alzheimer's disease dementia. Blood NfL also inversely correlates with cognitive performance in those conditions. However, few studies have assessed NfL as a biomarker of global cognition in individuals demonstrating mild cognitive deficits who are at risk for vascular-related cognitive decline.

View Article and Find Full Text PDF

Objective: Depression in later life is associated with a two-fold increased risk of dementia. It is not clear to what extent potentially modifiable risk factors account for this association.

Method: Older adults (age 50 + ) with objective health measures ( = 14,014) from the Canadian Longitudinal Study on Aging were followed for a mean duration of 35 months.

View Article and Find Full Text PDF

Importance: Neuropsychiatric syndromes (NPSs) are common in neurodegenerative disorders (NDDs); compromise the quality of life of patients and their care partners; and are associated with faster disease progression, earlier need for nursing home care, and poorer quality of life. Advances in translational pharmacology, clinical trial design and conduct, and understanding of the pathobiology of NDDs are bringing new therapies to clinical care.

Observations: Consensus definitions have evolved for psychosis, agitation, apathy, depression, and disinhibition in NDDs.

View Article and Find Full Text PDF

Whether individuals with mild cognitive impairment (MCI) and a history of major depressive disorder (MDD) are at a higher risk for cognitive decline than those with MCI alone is still not clear. Previous work suggests that a reduction in prefrontal cortical theta phase-gamma amplitude coupling (TGC) is an early marker of cognitive impairment. This study aimed to determine whether using a TGC cutoff is better at separating individuals with MCI or MCI with remitted MDD (MCI+rMDD) on cognitive performance than their clinical diagnosis.

View Article and Find Full Text PDF

Background: Apathy and depression are common neuropsychiatric symptoms across neurodegenerative disorders and are associated with impairment in several cognitive domains, yet little is known about the influence of sex on these relationships.

Objectives: We examined the relationship between these symptoms with neuropsychological performance across a combined cohort with mild or major neurodegenerative disorders, then evaluated the impact of sex.

Design, Setting And Participants: We conducted a cohort analysis of participants in the COMPASS-ND study with mild cognitive impairment (MCI), vascular MCI, Alzheimer's disease, mixed dementia, Parkinson's disease, frontotemporal dementia, and cognitively unimpaired (CU) controls.

View Article and Find Full Text PDF

Introduction: Hypertension and diabetes are common cardiovascular risk factors that increase Alzheimer's disease (AD) risk. However, it is unclear whether AD risk differs in hypertensive individuals with and without diabetes.

Methods: Cognitively normal individuals (N = 11,074) from the National Alzheimer's Coordinating Center (NACC) were categorized as having (1) hypertension with diabetes (HTN+/DM+), (2) hypertension without diabetes (HTN+/DM-), or (3) neither (HTN-/DM-).

View Article and Find Full Text PDF

Objectives: To identify data-driven cognitive profiles in older adults with remitted major depressive disorder (rMDD) with or without mild cognitive impairment (MCI) and examine how the profiles differ regarding demographic, clinical, and neuroimaging measures.

Design: Secondary cross-sectional analysis using latent profile analysis.

Setting: Multisite clinical trial in Toronto, Canada.

View Article and Find Full Text PDF